SLC2A3 and lung carcinoma: These findings were corroborated by other studies using EGFR inhibitors in lung cancer cells, in which they observed a clear EGFR-dependent glycolytic metabolism phenotype adoption, as they observed important decreases in the expression of GLUT3 and HXKII proteins in response to treatment with first generation TKIs [12,42].